Coronavirus: New drug helps COVID - 19 patients breathe on own

4 minutes

11 May The following is a roundup of some of the latest scientific studies on the new coronavirus and the effort to find treatments and vaccines for COVID-19, the illness caused by virus HIV.

Innovative drug helps COVID -- 19 patients breathe on their own.

When a new monoclonal antibody drug was added to treatments directed to invasive COVID 19 patients who were still breathing on their own, the drug lenzilumab of Humanigen Inc - improved their odds of not needing invasive mechanical ventilation, found researchers.The 540 patients in the standard trial were already receiving a variety of randomized treatments.Half received lenzilumab through three intravenous infusions also.In a paper published on Wednesday on medRxiv after peer review, the research team found that patients in the group of Lenzilumab had a 54% better chance of surviving without mechanical ventilation.In patients with steroids and Gilead Sciences mechanical drug remdesivir the addition of lenzilumab improved survival by 92% without the need for antiviral ventilation.In patients under 85 whose immune system was in the early stages of triggering a life-threatening inflammatory response, lenzilumab improves the odds of ventilator-free survival by nearly threefold.Humanigen Chief Executive and study coauthor Dr. Cameron Durrant said his team believes that the results in COVID 19 treatment show a substantial improvement.What do you think about your friends:

A controversial new paper based on virus tests suggests a possible explanation for why some COVID19 survivors still test positive for eukaryotic RNA tests months later.Small fragments of Infected Cells' Genetic instructions could be integrated into coronavirus's genome.The fragments that got inserted into the cell's genetic code came mainly from the tail end of the viral genome and can only induce the cell to create infectious virus.However, they could be enough to trigger a positive result on PCR – 19 tests.There is no evidence that the process of these integrations into the genome causes harm, said study leader Rudolf Jaenisch of the Whitehead Institute for Biomedical Research of MIT, adding that the researchers believe that is highly unlikely.Other experts have said the findings, reported in the journal PNAS on Thursday, likely reflect experimental effects of unintended methods.The researchers have seen the phenomenon only in test tubes.They are trying to find direct evidence for SARS-CoV 2 sequences integrated into the genome in patients, but these experiments are technically very challenging, Jaenisch said.The vaccines from Pfizer BioNTech BNTX.O and Moderna use messenger RNA to teach cells to make a protein that resembles a site on the virus.The cell breaks down RNA and gets rid of it quickly.There is no evidence that the vaccine RNA can be embedded in vaccine cells, and we think this is highly unlikely, Jaenisch said.The negligible risks of complications from COVID 19 would be a very strong incentive to get the vaccine, he said, citing high risks from the shot.Then read:

The COVID – 19 monitoring home may keep patients out of hospital.

According to a new study, a home monitoring program for patients with COVID - 19 may be associated with lower odds of hospitalization.At the Cleveland Clinic, doctors monitored 3,975 COVID 19 patients for up to 14 days after a positive test remotely.In a study published on Thursday in the JAMA Health Forum, they compared demographics of healthcare use from those patients and 3,221 similar patients who did not participate in the program.A month after diagnosis, the participants in the Home Monitoring Program were 27% less likely to have been hospitalized than nonparticipants, although they had about a two-fold higher chance of outpatient visits with the home monitoring program.As the pandemic continued and we learned more and more about the outcomes of the program and the natural course of infection by COVID in groups of patients, we were able to fine tune the program to those with the highest risk, said Dr Anita Misra-Hebert, director of the Clinic's Healthcare Delivery Implementation Science Center.The trial was not randomized and does not provide conclusive evidence of the program's value.Instead, researchers write that the results support the need for randomized trials to evaluate home monitoring programs after COVID 19 diagnosis.What's your favorite thing to do after you’ve written my letter?

Open https: 3 c 7 R 3 Bl in an external browser for a Reuters graphic on vaccines in development.

  • Comments
Loading comments...